Dellinger, Ryan W.
Santos, Santiago Roel
Morris, Mark
Evans, Mal
Alminana, Dan
Guarente, Leonard
Marcotulli, Eric
Article History
Received: 1 September 2017
Revised: 17 October 2017
Accepted: 26 October 2017
First Online: 24 November 2017
Change Date: 20 August 2018
Change Type: Correction
Change Details: The original version of the published Article contained an incorrect citation for reference 20 “Hubbard, B. P. & Sinclair, D. A. Measurement of sirtuin enzyme activity using a substrate-agnostic fluorometric nicotinamide assay. <i>Methods Mol. Biol</i>. 1077, 167–177 (2013).” The citation for reference 20 has been changed to “Cheng, Y. <i>et al</i>. SIRT1 activation by pterostilbene attenuates the skeletal muscle oxidative stress injury and mitochondrial dysfunction induced by ischemia reperfusion injury. <i>Apoptosis</i> 21 (8), 905-916 (2016)”. The original version of the published Article did not list a source for the placebo pills or the investigational product NRPT in the Intervention section of Methods. The last sentence of the Intervention section of Methods now lists the source for the placebo pills and the investigational product NRPT as follows: “The matched placebo pills and the investigational product (NRPT) were provided by Elysium Health (New York, NY)”. This has now been corrected in the PDF and HTML versions of the Article.
Competing interests
: NRPT (commercially known as Basis) is a supplement marketed by Elysium Health, which funded the trial. To avoid any bias in the collection of the trial data, the trial itself was conducted independently by KGK Synergize, a CRO based in London, Ontario. R.W.D., S.R.S., M.M., D.A., L.G., and E.M. are all employees of Elysium Health and all own shares in the company.